New research suggests that patients who stop using blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Research printed in a major medical journal points out that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals purchasing these drugs need to be aware of the risk of quick rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.
That rate of regain suggests a return to starting weight within about one and a half years.
Weighing Therapies
The research, which examined 37 of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with older methods.
The team emphasize that people who lose weight through dieting generally see a more gradual weight regain—around 100 grams monthly—after stopping.
The Reason for the Quick Regain
Nutrition scientists believe the mechanism of the drugs accounts for the heightened rebound.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Disease?
The NHS recommend the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, due to the significant potential of weight regain, the therapy should be considered life-long.
This view is echoed by pharmaceutical companies, who note that the findings "emphasize the chronic character of excess weight," comparing it to managing conditions like diabetes.
Patient Experiences
Users who have stopped the jabs explain a powerful return of appetite.
"I experienced a trigger that goes on and you become extremely hungry," recalled an individual.
This difficulty is exacerbated if individuals have not adopted permanent dietary or behavioural changes during treatment.
Widespread Interest
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is higher among women compared to males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, experts stress that while the jabs are effective agents for weight loss, they are not a permanent cure and maintained weight loss hinges on integrated behavioural management.
